EUCTR2008-003290-41-BE进行中（未招募）不适用
A Multi-center, open-label, multiple dose, dose finding study exploring the safety and tolerability of Beraprost Sodium Modified Release in PAH patients
ung Rx0 个研究点目标入组 20 人开始时间: 2008年12月9日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •A PAH patient must meet all of the following criteria:
- •1) Is male or female between the ages of 18 and 75 years of age, inclusive;
- •2) Has idiopathic or familial PAH, PAH associated with collagen vascular disease, or PAH induced by anorexigens;
- •3) Is clinically stable, as determined by the Investigator
- •4) Has previously undergone a cardiac catheterization which is consistent with PAH, specifically PAPm = 25mmHg (at rest), PCWP (or left ventricular end diastolic pressure) = 15mmHg, and PVR > 3 wood units;
- •5) Has been on a course of an endothelial receptor antagonist (ERA) or phosphodiesterase inhibitor (PDE-5) or the combination for at least 90 days at the time of the Baseline visit;
- •6) Has an unencouraged six-minute walk distance (6MWD) between 300 and 600 meters at the screening visit;
- •7) Is able to communicate effectively with study personnel;
- •8) Is considered to be reliable, willing, cooperative and compliant with the study protocol requirements;
- •9) Provides voluntary, written informed consent before participating in the study;
- •10) Is, if female, physiologically incapable of childbearing or is practicing an acceptable method of birth control (e.g. surgical sterilization, approved hormonal contraceptives, barrier methods [ such as a condom or diaphragm] used with spemicide, or an intrauterine device).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Any Patient who meets any of the following criteria will be excluded from the study:
- •1) Has pulmonary venous hypertension, pulmonary veno-occlusive disease, Pulmonary capillary hemangiomatosis , severe chronic obstructive pulmonary disease , Pulmonary Hypertension related to congenital heart disease, or chronic thromboembolic pulmonary hypertension;
- •2) Is pregnant or lactating;
- •3) Has a known intolerance to beraprost sodium or prostanoids;
- •4) Has a pre-existing condition that could interfere with the absorption, distribution, metabolism, or excretion of drugs;
- •5) Current use of tobacco products;
- •6) Known history of syncope
- •7) Has, in the opinion of the Investigator, any concomitant disease other than those accepted as part of the inclusion criteria that would compromise the patient or the study;
- •8) Has had a change in or discontinued any PAH medication (with the exception of anticoagulants) within 30 days prior to the Baseline visit;
- •9) Has received any prostanoid therapy within 30 days prior to the Baseline visit or be scheduled to receive additional prostanoid therapy during the study except for acute vasodilstory testing;
- •10) Has received any investigational medication within 30 days prior to the Baseline visit or be scheduled to receive another investigational drug during the course of this study;
- •11) In the opinion of the investigator, may be unable to comply with the study protocol;
- •12) Has any pre exisiting disease known to cause pulmonary hypertension (e.g. obstructive lung disease, parasitic disease affecting the pulmonary system, sickle cell anemia, mitral valve stenosis, portal hypertension) other than those listed in the inclusion criteria;
- •13) Has donated blood or plasma or has lost a volume of blood > 450mL within six weeks prior to the Baseline visit.
- •14) Has an ongoing hemorrhagic condition (e.g. upper digestive tract hemorrhage, hemoptysis, etc), or has a pre-existing condition that, in the investigator’s judgment, may increase the risk for developing hemorrhage during the study (e.g. hemophilia). However, transient hemorrhage (e.g. epistaxis, normal menstrual bleeding, gingival bleeding, hemorrhoidal hemorrhage, etc.) would not preclude enrollment.
研究者
相似试验
进行中（未招募）
不适用
A Multi-center, open-label, multiple dose, dose finding study exploring the safety and tolerability of Beraprost Sodium Modified Release in PAH patientsPulmonary Arterial HypertensionMedDRA version: 9.1Level: LLTClassification code 10064911Term: Pulmonary arterial hypertensionEUCTR2008-003290-41-IEungRx10
进行中（未招募）
1 期
Study of recombinant factor VIIa fusion protein (rVIIa-FP, CSL689) for on-demand treatment of bleeding episodes in patients with hemophilia A or B with inhibitors.Hemophilia A with inhibitors, Hemophilia B with inhibitorsMedDRA version: 20.0Level: LLTClassification code 10053751Term: Hemophilia A with anti factor VIIISystem Organ Class: 100000004850MedDRA version: 20.0Level: LLTClassification code 10053752Term: Hemophilia B with anti factor IXSystem Organ Class: 100000004850EUCTR2012-001309-26-DECSL Behring GmbH54
进行中（未招募）
1 期
Study of recombinant factor VIIa fusion protein (rVIIa-FP, CSL689) for on-demand treatment of bleeding episodes in patients with hemophilia A or B with inhibitors.Hemophilia A with inhibitors, Hemophilia B with inhibitorsMedDRA version: 18.0Level: LLTClassification code 10053751Term: Hemophilia A with anti factor VIIISystem Organ Class: 100000004850MedDRA version: 18.0Level: LLTClassification code 10053752Term: Hemophilia B with anti factor IXSystem Organ Class: 100000004850EUCTR2012-001309-26-ESCSL Behring GmbH54
进行中（未招募）
1 期
Study of recombinant factor VIIa fusion protein (rVIIa-FP, CSL689) for on-demand treatment of bleeding episodes in patients with hemophilia A or B with inhibitors.EUCTR2012-001309-26-GBCSL Behring GmbH54
进行中（未招募）
1 期
Study of recombinant factor VIIa fusion protein (rVIIa-FP, CSL689) for ondemand treatment of bleeding episodes in patients with hemophilia A or B with inhibitorsHemophilia A or BMedDRA version: 20.0Level: LLTClassification code 10053752Term: Hemophilia B with anti factor IXSystem Organ Class: 100000004850MedDRA version: 20.0Level: LLTClassification code 10053751Term: Hemophilia A with anti factor VIIISystem Organ Class: 100000004850EUCTR2012-001309-26-ITCSL BEHRING GMBH25